Efficacy of dupilumab in moderate and severe atopic dermatitis
Efficacy of dupilumab in moderate and severe atopic dermatitis
About this item
Full title
Author / Creator
Publisher
Madrid: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Madrid: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Treatment responses may differ between patients with severe versus moderate atopic dermatitis (AD).
Objectives
To assess dupilumab response by baseline AD severity in adolescent and adult patients with moderate‐to‐severe AD.
Methods
We assessed dupilumab response by baseline AD severity in 1719 patients aged ≥12 years with...
Alternative Titles
Full title
Efficacy of dupilumab in moderate and severe atopic dermatitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_24be7f202b024830b0a2eca0f0e43c5b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_24be7f202b024830b0a2eca0f0e43c5b
Other Identifiers
ISSN
2768-6566
E-ISSN
2768-6566
DOI
10.1002/jvc2.100
